Jessica Fye
Stock Analyst at JP Morgan
(4.02)
# 504
Out of 4,905 analysts
192
Total ratings
58.4%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines | Maintains: Overweight | $321 → $345 | $294.55 | +17.13% | 3 | Jul 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $58 → $60 | $56.45 | +6.29% | 13 | Jul 16, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $338 → $348 | $320.53 | +8.57% | 7 | Jul 16, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $515 → $517 | $459.81 | +12.44% | 9 | Jul 14, 2025 | |
| INCY Incyte | Maintains: Neutral | $68 → $67 | $67.86 | -1.27% | 7 | Jul 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $108 → $113 | $57.29 | +97.24% | 4 | Jul 14, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $350 → $330 | $292.01 | +13.01% | 17 | Jul 8, 2025 | |
| INSM Insmed | Maintains: Overweight | $90 → $111 | $102.56 | +8.23% | 8 | Jul 8, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $48 | $41.75 | +14.97% | 5 | Jun 12, 2025 | |
| MRNA Moderna | Maintains: Underweight | $33 → $26 | $31.26 | -16.83% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $116 | $110.02 | +5.44% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $8.61 | +50.99% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $245 | $169.90 | +44.20% | 12 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $36.32 | +37.67% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $16.02 | +74.78% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $112.87 | +85.17% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $14.00 | +71.43% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $29.22 | -11.02% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.75 | +155.32% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $31.11 | +73.58% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $51.93 | -24.90% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $13.22 | -1.66% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $24.94 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $6.93 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.17 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $15.83 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $41.59 | +82.74% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.66 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.43 | +1,438.46% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.23 | +469.11% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.35 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $7.00 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.54 | - | 1 | Feb 8, 2018 |
BeOne Medicines
Jul 17, 2025
Maintains: Overweight
Price Target: $321 → $345
Current: $294.55
Upside: +17.13%
Halozyme Therapeutics
Jul 16, 2025
Maintains: Neutral
Price Target: $58 → $60
Current: $56.45
Upside: +6.29%
Alnylam Pharmaceuticals
Jul 16, 2025
Maintains: Overweight
Price Target: $338 → $348
Current: $320.53
Upside: +8.57%
Vertex Pharmaceuticals
Jul 14, 2025
Maintains: Overweight
Price Target: $515 → $517
Current: $459.81
Upside: +12.44%
Incyte
Jul 14, 2025
Maintains: Neutral
Price Target: $68 → $67
Current: $67.86
Upside: -1.27%
BioMarin Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $108 → $113
Current: $57.29
Upside: +97.24%
United Therapeutics
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $292.01
Upside: +13.01%
Insmed
Jul 8, 2025
Maintains: Overweight
Price Target: $90 → $111
Current: $102.56
Upside: +8.23%
Ionis Pharmaceuticals
Jun 12, 2025
Maintains: Neutral
Price Target: $45 → $48
Current: $41.75
Upside: +14.97%
Moderna
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $31.26
Upside: -16.83%
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $110.02
Upside: +5.44%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.61
Upside: +50.99%
May 2, 2025
Maintains: Overweight
Price Target: $200 → $245
Current: $169.90
Upside: +44.20%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $36.32
Upside: +37.67%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $16.02
Upside: +74.78%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $112.87
Upside: +85.17%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.00
Upside: +71.43%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $29.22
Upside: -11.02%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $11.75
Upside: +155.32%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $31.11
Upside: +73.58%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $51.93
Upside: -24.90%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $13.22
Upside: -1.66%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $24.94
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $6.93
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.17
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $15.83
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $41.59
Upside: +82.74%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.66
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.43
Upside: +1,438.46%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.23
Upside: +469.11%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.35
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $7.00
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $7.54
Upside: -